Search Results for: laquinimod

By Jewish Business News On Sunday, May 7th, 2017

Teva and Active Biotech Announce CONCERTO trial of Laquinimod trial fails

   Teva Pharmaceutical Industries Ltd. and its partner Active Biotech reported on Friday that the CONCERTO trial of its ethical drug laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS) More...

By Jewish Business News Service On Sunday, January 26th, 2014

Teva and Active Biotech to Continue Laquinimod for Multiple Sclerosis Development Despite EMA

– Europe’s Committee for Medicinal Products for Human Use: The risk-benefit profile of laquinimod is not favorable at this time. –  – Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and More...

By Ilan Shavit On Tuesday, October 1st, 2013
1 Comment

Oral Laquinimod for Multiple Sclerosis May Reduce Brain Damage Caused by Neurodegeneration

  – Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) announced today the publication of a pre-planned analysis of the Phase III ALLEGRO study demonstrating More...

By Michael Ordman On Monday, October 7th, 2013

Good news from Israel

– In the 6th Oct 2013 edition of Israel’s good news, the highlights include: ·        Israeli scientists have made an important discovery in the fight against leukemia. ·        Ethiopian-born More...

By Shiri Habib-Valdhorn On Wednesday, October 2nd, 2013

Credit Suisse: Copaxone sales to plunge 90%

– Credit Suisse sees Copaxone sales falling from $4 billion annually to $400, 000 in 2019 and predicts annual sales of over $1 billion for Laquinimod. – Copaxone – Teva Pharmaceutical Industries More...

Wordpress site Developed by Fixing WordPress Problems